US Pharm. 2012;37(4):44.
The FDA issued three draft guidance documents on
biosimilars to assist the industry in developing these drugs in the
U.S. The FDA is seeking public comment on the following documents:
Scientific Considerations in Demonstrating Biosimilarity to a Reference
Product; Quality Considerations in Demonstrating Biosimilarity to a
Reference Protein Product; and Biosimilars: Questions and Answers
Regarding Implementation of the Biologics Price Competition and
Innovation Act of 2009.
“When it comes to getting new biosimilar products on the
market, FDA has taken an innovative approach to supporting their
development at every step of the process,” said Janet Woodcock, MD,
director of the FDA’s Center for Drug Evaluation and Research. “These
draft documents are designed to help industry develop biosimilar
versions of currently approved biological products, which can enhance
competition and may lead to better patient access and lower cost to
The FDA will provide instructions on how to submit comments in an upcoming Federal Register notice.
U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date,
authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings,
including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations,
long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students,
other health professionals and individuals interested in health management. Pharmacists licensed in the U.S. can earn
Continuing Education credits through Postgraduate Healthcare Education, LLC, accredited by the Accreditation Council for Pharmacy Education (ACPE)
as a provider of continuing pharmacy education.
Copyright © 2000 - 2013 Jobson Medical Information LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited.